• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NuMe Health becomes MicroBiome Therapeutics

NuMe Health becomes MicroBiome Therapeutics

August 7, 2013
CenterWatch Staff

NuMe Health has changed its name to MicroBiome Therapeutics and has hired Steve Orndorff, Ph.D., as chief executive officer.

Boulder, Colo.-based MicroBiome Therapeutics (MBT) is a biotechnology company developing medical food and pharmaceutical products to improve health status by interacting with the human microbiome in specific ways. The company aims to be a leader in the development of evidence-based microbiome modulators—therapies designed to alter bacteria populations and their environment in the gastrointestinal (GI) tract to treat and prevent serious health conditions.

"Our new name reflects the fact that our R&D efforts are focused on developing novel therapies that work by altering the GI microbiome," said John Elstrott, Ph.D., chairman of MBT. "The explosion of knowledge about the human microbiome makes this an exciting time to be a pioneer in the emerging field of microbiome modulators."

MBT's microbiome modulators act on multiple factors in the GI environment, providing specialized nutrition that augments the growth of targeted desirable bacteria strains and modifying factors such as the endocrine response that affects appetite, metabolism and energy storage.  MBT's lead product, NM504, contains a proprietary combination of prebiotic and other naturally occurring ingredients formulated to help diabetic individuals achieve healthy blood glucose levels and manage their body weight. It is currently being tested in a clinical trial for the management of insulin sensitivity and blood glucose levels in patients with type 2 diabetes, as well as in a pilot clinical study as adjunctive therapy to the diabetes drug metformin.

Previously, Orndorff was CEO of Ariel Pharmaceuticals, a specialty pharmaceutical company with a neurological focus.  He also has been CEO of Accera, which commercialized a prescription-only pharmacogenomic medical food for Alzheimer's patients and Univera Pharmaceuticals, a developer of novel anti-inflammatory drugs derived from natural products.

Earlier, Orndorff held R&D and manufacturing positions at PharmaLogix, ZeaGen and Monsanto's NutraSweet subsidiary. He is chairman of the Colorado Institute for Drug, Device & Diagnostic Development, past chairman of the Colorado BioScience Association and past president of the Society for Industrial Microbiology. 

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing